Clinical Trial Results: Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing nilotinib in Parkinson's disease with and without dementia; results completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Parkinson Disease with Dementia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Georgetown University | Conditions: Parkinson Disease, Parkinsons Disease With Dementia | Phase 2 | Status: COMPLETED | Results posted: 2026-06-12